50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
The 3-Stock Retirement Blueprint (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
The 3-Stock Retirement Blueprint (Ad)
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
The 3-Stock Retirement Blueprint (Ad)
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
The 3-Stock Retirement Blueprint (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
The 3-Stock Retirement Blueprint (Ad)
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
The 3-Stock Retirement Blueprint (Ad)
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
The 3-Stock Retirement Blueprint (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
The 3-Stock Retirement Blueprint (Ad)
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
The 3-Stock Retirement Blueprint (Ad)
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
The 3-Stock Retirement Blueprint (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
China using civilian ships to enhance navy capability, reach
The 3-Stock Retirement Blueprint (Ad)
German leader seeks energy deals, alliances on Gulf trip
Saudi Arabia's triumphant week reclaims the West's embrace
The 3-Stock Retirement Blueprint (Ad)
5 Monthly Dividends Yielding 7.9% to 18.3%
Kim Kardashian culls Dolce&Gabbana archives for Milan show
NASDAQ:AMPH

Amphastar Pharmaceuticals - AMPH Stock Forecast, Price & News

$27.56
-0.03 (-0.11%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.10
$27.59
50-Day Range
$27.56
$37.75
52-Week Range
$18.12
$44.46
Volume
222,635 shs
Average Volume
294,510 shs
Market Capitalization
$1.35 billion
P/E Ratio
15.48
Dividend Yield
N/A
Price Target
$38.50

Amphastar Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
39.7% Upside
$38.50 Price Target
Short Interest
Bearish
5.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
0.30mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.75 M Sold Last Quarter
Proj. Earnings Growth
14.38%
From $1.46 to $1.67 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

169th out of 1,075 stocks

Pharmaceutical Preparations Industry

64th out of 532 stocks

AMPH stock logo

About Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Stock News Headlines

AMPH Amphastar Pharmaceuticals, Inc.
Amphastar Receives FDA Approval for Vasopressin
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Company Calendar

Last Earnings
8/08/2022
Today
9/24/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMPH
Employees
1,761
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.50
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+39.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$62.12 million
Pretax Margin
24.53%

Debt

Sales & Book Value

Annual Sales
$437.77 million
Cash Flow
$1.91 per share
Book Value
$9.31 per share

Miscellaneous

Free Float
35,389,000
Market Cap
$1.35 billion
Optionable
Optionable
Beta
0.73

Key Executives

  • Dr. Ziping  Luo Ph.D.Dr. Ziping Luo Ph.D. (Age 72)
    Chairman, Chief Scientist & COO
    Comp: $1.34M
  • Dr. Yongfeng  Zhang Ph.D.Dr. Yongfeng Zhang Ph.D. (Age 75)
    Co-Founder, Pres, CEO, Chief Scientific Officer & Director
    Comp: $1.93M
  • Mr. William J. Peters M.B.A.Mr. William J. Peters M.B.A. (Age 54)
    CFO, Exec. VP of Fin., Treasurer & Director
    Comp: $1.11M
  • Mr. Jacob Liawatidewi M.B.A. (Age 48)
    Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director
    Comp: $773.69k
  • Mr. Rong  Zhou M.S.Mr. Rong Zhou M.S. (Age 63)
    Exec. VP of Production Center
    Comp: $842.77k
  • Dan Dischner M.B.A.
    VP of HR & Corp. Communication
  • Tony Marrs M.B.A.
    M.P.H., Sr. VP of Regulatory Affairs & Clinical Operations
  • Mr. Peter Langosh (Age 69)
    VP of Operational Improvement and VP of Internal Audit













AMPH Stock - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price forecast for 2022?

3 Wall Street analysts have issued 12 month price targets for Amphastar Pharmaceuticals' stock. Their AMPH share price forecasts range from $32.00 to $44.00. On average, they predict the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 39.7% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2022?

Amphastar Pharmaceuticals' stock was trading at $23.29 on January 1st, 2022. Since then, AMPH stock has increased by 18.3% and is now trading at $27.56.
View the best growth stocks for 2022 here
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its earnings results on Monday, August, 8th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.03. The company earned $123.47 million during the quarter, compared to analyst estimates of $118.17 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 18.51% and a net margin of 19.06%. During the same period last year, the firm posted $0.21 earnings per share.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (6.70%), State Street Corp (3.14%), Nantahala Capital Management LLC (0.00%), Caption Management LLC (0.00%), Assenagon Asset Management S.A. (0.86%) and Northern Trust Corp (0.85%). Insiders that own company stock include David Maris, Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends
.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $27.56.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.35 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.78 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

The company employs 1,761 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296.

This page (NASDAQ:AMPH) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.